Australia is allowing legal access to MDMA-assisted therapy, unexpectedly turning itself into a guinea pig ahead of potential FDA approval in the United States.
The U.S.-based Multidisciplinary Association for Psychedelic Studies , the organization that has applied for FDA approval, sponsored the research.
His team is working on shortening MDMA’s half-life and eliminating a weak addictive property. In the lab, a chemist carefully pours a clear solution into a flask from a series of test tubes. Inside, each contains an analog of the drug. Nearby, a colleague handles a small jar filled with crystalline yellow precursor, while another switches off a contraption with a spinning sphere.
The state’s favorable regulatory approach has meant Australian-based biotech companies working in MDMA and psilocybin have set up there, said Suzy Madar, an intellectual property lawyer who specializes in health.“It’s not common for the TGA to take a lead in this kind of area,” said Winlo of Emyria. “This puts a lot of attention on the various players in this space to see how we proceed.”
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
AUKUS: First cohort of Australian submariners graduate United States Navy's 'Nuke School'The graduates are important in Australia's plans to field a fleet of nuclear-powered, conventionally-armed submarines under the trilateral Australia-United Kingdom-United States partnership.
続きを読む »
Jacksonville police arrest 8 in MDMA drug bustAccording to arrest reports, JSO’s Narcotics Street Team went all over the city as undercover officers posing as drug abusers that were attempting to buy.
続きを読む »
US FDA declines to approve Regeneron's higher-dose Eylea, shares tumbleU.S. health regulators said on Tuesday they declined to approve a higher-dose version of Regeneron Pharmaceuticals' drug Eylea for treatment of a disease that is the leading cause of blindness among the elderly, and the company's shares fell on the setback to its effort to defend the blockbuster treatment against a fast-gaining rival.
続きを読む »
Myasthenia Gravis Drug Gets FDA NodThe monoclonal antibody rozanolixizumab (Rystiggo) is indicated to treat adults with the two most common subtypes of generalized myasthenia gravis.
続きを読む »
Dozens of frozen fruit products sold at 6 major retailers recalled by FDAIn the recall notice, SunOpta and the FDA urged consumers to check their freezers for the recalled product and to not consume it, but rather discard the product or return it to the store for a full refund.
続きを読む »
FDA Decision on Bimekizumab Approval for Psoriasis DelayedThe FDA's review of the BLA for bimekizumab for the treatment of psoriasis is continuing. A decision on the approval application has been delayed until the third quarter of this year. DermTwitter
続きを読む »